Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 8, 2016

View Archived Issues

Vyriad enters global license agreement with Stinginn

Eisai reviews accomplishments of first quarter of fiscal 2016

Merck & Co. patents BACE1 and -2 inhibitors

Sumitomo Dainippon Pharma discloses Nav1.7 channel blockers

Millennium Pharmaceuticals describes Nampt inhibitors

Scripps Research Institute develops MCT1 and/or MCT4 inhibitors

MyoKardia presents cardiac myosin activators

MMRF and University of Michigan collaborate on a new molecular profiling initiative

Autologous BMC is safe and effective in treating patients with atrophic non-unions

FDA accepts Merck & Co.'s MK-1293 NDA for review

Mylan completes public offer settlement with Meda

CheckMate 026 phase III study of Opdivo does not meet primary endpoint

ZSYM73 affibody in a mouse model of AD

Shire reports recent developments of second quarter 2016

UT Southwestern receives funding from NCI to target rising rates of kidney cancer

Hematogenix announces launch of Ventana PD-L1 (SP142) and (SP263) assays

FDA approves Merck & Co.'s Keytruda for patients with recurrent or metastatic HNSCC

Lantern Pharma to evaluate BioNumerik's Tavocept

FDA grants orphan drug designation to vedolizumab

Boehringer Ingelheim begins phase II trial of BI-425809 in patients with schizophrenia

Phase II trial of volixibat in patients with NASH recruiting patients

Tolerogenic nanoparticles improve biologic drug efficacy

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Aug. 3, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...